Back to Investors

Clayton Dubilier & Rice

Evidence PackPROIndependent
Private EquityNEW YORK, NY, United States Founded 1978 Website
AUM
$50B
Ownership
independent
Stakeability
37 / VERY LOW
Priority
Tier 1
Employees
N/A

Clayton, Dubilier & Rice, LLC (CD&R) is a private equity firm headquartered in New York, NY, with additional offices in London. The company was established in 1978 and has since become one of the leading private equity firms globally. CD&R focuses on investing in and partnering with established ...

SEC RegisteredFund PerformanceLegal Filings

Coverage

25%

Adaptive profile: standard

Signals present
3/12
SEC / ADVFund Performance(12)BDC Exposure(0)13F Holders(0)Team(0)ILS Deals(0)Regulatory(0)Legal(8)Lobbying(0)Hiring(0)News(0)GP Stakes Deals(0)

Data Freshness

Recent Changes

Stakeability Breakdown

37 / 100
Fund PerformanceAUM growth and fundraising track record
31
Team StabilityLeadership continuity and key person risk
6
Market PositionBrand strength and competitive positioning
37
Succession ReadinessNext-gen leadership and governance structure
60
Transaction FeasibilityLikelihood of a stake transaction
22
Unable to load signal breakdown.

IC Risk Memo

PRO

Investment committee-ready memo with risk analysis and recommendation

Click "Generate Memo" to create an IC-ready analysis

Includes risk factors, citations, and recommendation

CRD Number
160492
SEC File Number
801-73344
Registration Type
Registered
Filing Date
Mar 31, 2025
Employee Count
N/A
Discretionary AUM
$82.2B
Private Funds
42
PE Funds
42
VC Funds
N/A
RE Funds
N/A
Hedge Funds
N/A
Gross Assets (Private)
$81.1B
Source: SEC IAPD

Fund performance data requires Professional

Upgrade your plan to access this section.

Upgrade

Team intelligence requires Professional

Upgrade your plan to access this section.

Upgrade

Competition mapping requires Professional

Upgrade your plan to access this section.

Upgrade

Legal filings require Professional

Upgrade your plan to access this section.

Upgrade

No GP stakes deals recorded

This GP has not sold a minority stake, making it a potential target.